



Pradip B. Gandhi & Co. LLP
(Formerly Known as Pradip B. Gandhi and Co.)
Chartered Accountants

819, Iconic Shyamal, Shyamal Cross Road,
Ahmedabad- 380015, Gujarat, INDIA.

CA Pradip Gandhi

FCA, B.Com., LLB

+91-9825139076 ✉ pradip@pbgandco.com

CA Amit Lakhtariya

FCA, DISA, B.Com.

+91-9376139815 ✉ amit@pbgandco.com

079- 40093076, +91-9374476076

✉ incometax@pbgandco.com

www.pbgandco.com

INDEPENDENT AUDITOR REPORT

TO THE MEMBERS OF BRAINIAC HEALTHCARE PRIVATE LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the standalone financial statements of **Brainiac Healthcare Private Limited** ("the Company"), which comprise the Balance Sheet as at 31 March 2024, and the Statement of Profit and Loss for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2024, and its profit, for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Key Audit Matters are not applicable to the Company as it is an unlisted company.



Information other than the financial statements and auditors report thereon

The Company's Board of Directors is responsible for the other information. The other information obtained at the date of this auditor's report is director's report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the financial statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the



aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Report on other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143 (11) of the Act, is not applicable.
2. As required by section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
 - c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014).
 - e) On the basis of written representations received from the directors as on 31 March 2024, taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2024, from being appointed as a director in terms of Section 164(2) of the Act.
 - f) Reporting with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls is not applicable to the Company in view of exemptions given in the notification dated 13th June 2017 issued by Ministry of Corporate Affairs.
 - g) Since the Company is a private limited company, provisions of section 197 of the Act read with schedule V to the Act in respect of managerial remuneration are not applicable. Therefore, reporting as required by Section 197(16) of the Act is not applicable to the Company.
 - h) With respect to the other matters included in the Auditor's Report and to our best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
 - iii. There is no amount required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. To the best of our knowledge and belief, as disclosed in the financial statement,
 - no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity (ies), including foreign entities ("Intermediaries"), with the



understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company

- no funds have been received by the Company from any person(s) or entity (ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material mis-statement.

- v. The Board of Directors of the company have not proposed any dividend for the financial year ended 31 March, 2024.
- vi. Based on our examination, which included test checks, the Company has used accounting softwares for maintaining its books of account for the financial year ended March 31, 2024 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the softwares. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

For Pradip B Gandhi & Co LLP
(Formerly known as Pradip B. Gandhi & Co.)
Chartered Accountants



CA Amit Lakhtariya
Designated Partner
DPIN: 08221493
M. No. 117820

FRN: 0118674W/W101002
UDIN: 24117820BKAUUR4927

PLACE: AHMEDABAD
DATE: 16/09/2024

BRAINIAC HEALTHCARE PRIVATE LIMITED

(CIN: U85300GJ2021PTC124795)

(Address: B-24, VRUNDAVAN PARK NR. JANTA NAGAR, ODHAV AHMEDABAD 382415)

Balance Sheet as at 31 March 2024

(Rs in '000)

Particulars	Note	31 March 2024	31 March 2023
I. EQUITY AND LIABILITIES			
(1) Shareholders' funds			
(a) Share Capital	1	100.00	100.00
(b) Reserves and Surplus	2	(135.40)	(187.22)
Total		(35.40)	(87.22)
(2) Current liabilities			
(a) Short-term Borrowings	3	572.46	559.56
(b) Other Current Liabilities	4	494.55	309.25
Total		1,067.01	868.81
Total Equity and Liabilities		1,031.62	781.59
II. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	5	175.65	146.11
(ii) Intangible Assets	5	308.60	264.77
Total		484.26	410.88
(2) Current assets			
(a) Cash and cash equivalents	6	226.13	166.05
(b) Short-term Loans and Advances	7	317.73	199.41
(c) Other Current Assets	8	3.50	5.25
Total		547.36	370.71
Total Assets		1,031.62	781.59

See accompanying notes to the financial statements

As per our report of even date

For PRADIP B. GANDHI & CO. LLP

Chartered Accountants

Firm's Registration No. 118674W/W101002



CA Amit Lakhtariya


Designated Partner

Membership No. 117820

UDIN: 24117820BKAUUR4927

Place: Ahmedabad


Date: 16 September 2024

For and on behalf of the Board of
BRAINIAC HEALTHCARE PRIVATE LIMITED

KRUNAL PRAJAPATI

Director

09274943



RAJESHBHAI

PRAJAPATI

Director

09274944

Place: Ahmedabad

Date: 16 September 2024

BRAINIAC HEALTHCARE PRIVATE LIMITED

(CIN: U85300GJ2021PTC124795)

(Address: B-24, VRUNDAVAN PARK NR. JANTA NAGAR, ODHAV AHMEDABAD 382415)

Statement of Profit and loss for the year ended 31 March 2024

(Rs in '000)

Particulars	Note	31 March 2024	31 March 2023
Revenue from Operations		-	-
Other Income	9	1,370.12	929.52
Total Income		1,370.12	929.52
Expenses			
Purchases of Stock in Trade	10	162.40	-
Employee Benefit Expenses	11	350.00	118.00
Depreciation and Amortization Expenses	12	113.93	65.83
Other Expenses	13	691.97	672.79
Total expenses		1,318.30	856.62
Profit/(Loss) before Exceptional and Extraordinary Item and Tax		51.82	72.90
Exceptional Item		-	-
Profit/(Loss) before Extraordinary Item and Tax		51.82	72.90
Extraordinary Item		-	-
Profit/(Loss) before Tax		51.82	72.90
Tax Expenses	14		
- Current Tax		-	-
- Deferred Tax		-	(3.91)
Profit/(Loss) after Tax		51.82	76.81
Earnings Per Share (Face Value per Share Rs.10 each)			
-Basic (In Rs)	15	5.18	7.68
-Diluted (In Rs)	15	5.18	7.68


See accompanying notes to the financial statements

As per our report of even date

For PRADIP B. GANDHI & CO. LLP

Chartered Accountants

Firm's Registration No. 118674W/W101002


CA Amit Lakhtariya

Designated Partner

Membership No. 117820

UDIN: 24117820BKAUUR4927

Place: Ahmedabad


Date: 16 September 2024

For and on behalf of the Board of
BRAINIAC HEALTHCARE PRIVATE LIMITED
K.R. Prajapati

KRUNAL PRAJAPATI

Director

09274943


राजेश भैया प्रजापती
प्र.म.म.

RAJESHBHAI

PRAJAPATI

Director

09274944

Place: Ahmedabad

Date: 16 September 2024

Summary of significant accounting policies

A Corporate information

BRAINAC HEALTHCARE PRIVATE LIMITED ("the Company") is a private Company domiciled in India and incorporated on 09th August 2021 under the provisions of the Companies Act 2013. The Company is recognized as startup by the Department for Promotion of Industry and Internal Trade. The Startup is working in 'Healthcare & Lifesciences' Industry and 'Medical Devices Biomedical'.

B Basis for Preparation of Financial statements

These financial statements have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP) under the historical cost convention on accrual basis. Indian GAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with Rule 7 of the Companies (Accounts) Rules, 2014 and the provisions of the Act (to the extent notified). Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. All the divisions of the Company have normal operating cycle of less than twelve months; hence a period of twelve months has been considered for bifurcation of assets and liabilities into current and non-current as required by Schedule III to the Companies Act, 2013 for preparation of Financial Statements

The accounting policies adopted in the preparation of financial statements are consistent with those of previous year, except for the change in accounting policy explained below.

C Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make assumptions and estimates, which it believes are reasonable under the circumstances that affect the reported amounts of assets and liabilities on the date of financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Difference between the actual results and estimates are recognized in the period in which the results are known/materialized.

D Cash Flow Statement

Cash Flow Statement is not applicable to the company as it's a Small Company which is exempted from filing Cash Flow statement under Section 2(40) of Companies Act, 2013.

E Income taxes

Tax expenses comprises of current tax, deferred tax charge or credit, and adjustments of taxes for earlier years. In respect of amounts adjusted against securities premium / retained earnings, the corresponding tax effect is also adjusted against the securities premium / retained earnings or other reserves as the case may be as per the announcement of Institute of Chartered Accountants of India.

Provision for current tax is made as per the provisions of Income Tax Act, 1961.

Deferred tax charge or credit reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years and are measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date.

Deferred tax assets are recognized only to the extent there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits. Deferred tax assets are reviewed for the appropriateness of their respective carrying amounts at each balance sheet date.

F Property, Plant and Equipment

i) Property, plant & equipment are stated at cost of acquisition / construction less accumulated depreciation / amortization and accumulated impairment losses, if any. Gross carrying amount of all property, plant and equipment are measured using cost model.

ii) Cost of property, plant & equipment includes non-refundable taxes and duties, borrowing cost directly attributable to the qualifying asset and any directly attributable costs of bringing the asset to its working condition for its intended use and the present value of the expected cost for the dismantling / decommissioning of the asset.

iii) Parts (major components) of an item of property, plant and equipment having different useful lives are accounted as separate items of property, plant and equipment.

iv) Property, plant and equipment are eliminated from financial statement either on disposal or when retired from active use. Assets held for disposal are stated at net realizable value. Losses arising in the case of retirement of property, plant and equipment and gains or losses arising from disposal of property, plant and equipment are recognised in the statement of profit and loss in the year of occurrence.



v) Depreciation

a) Depreciation on property, plant & equipment is provided on a straight line method (SLM) over their useful lives which is in consonance of useful life mentioned in Schedule II to the Companies Act, 2013.

b) Depreciation methods, useful lives and residual values are reviewed at each financial year end and adjusted prospectively.

c) In the case of assets purchased, sold or discarded during the year, depreciation on such assets is calculated on pro-rata basis from the date of such addition or as the case may be, up to the date on which such asset has been sold or discarded.

G Intangible assets and amortization

i) Intangible assets are recognized only if it is probable that the future economic benefits attributable to the asset will flow to the Company and the cost of asset can be measured reliably. Intangible assets are stated at cost of acquisition / development less accumulated amortization and accumulated impairment loss, if any.

ii) Cost of an intangible asset includes purchase price including non-refundable taxes and duties, borrowing cost directly attributable to the qualifying asset and any directly attributable expenditure on making the asset ready for its intended use.

iii) Intangible assets (computer software) are amortized over its estimated useful lives of 5 years on straight-line method.

iv) Amortisation methods and useful lives are reviewed at each financial year end and adjusted prospectively.

v) Intangible assets under development comprises of cost incurred on intangible assets under development that are not yet ready for their intended use at the balance sheet date

H Impairment of assets

The carrying amounts of assets are reviewed at each balance sheet date for any indication of impairment based on internal / external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the asset's net selling price and value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life.

Based on the assessment done at each balance sheet date, recognized impairment loss is further provided or reversed depending on changes in circumstances. After recognition of impairment loss or reversal of impairment loss as applicable, the depreciation charge for the fixed asset is adjusted in future periods to allocate the asset's revised carrying amount, less its residual value (if any), on a systematic basis over its remaining useful life. If the conditions leading to recognition of impairment losses no longer exist or have decreased, impairment losses recognized are reversed to the extent it does not exceed the carrying amount that would have been determined after considering depreciation / amortization had no impairment loss been recognized in earlier years.

I Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

Interest:

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss.

J Foreign Currency transactions

Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction or that approximates the actual rate at the date of the transaction and difference arise on realization have been recognized as foreign exchange gains or losses as applicable.

Monetary items denominated in foreign currencies at the year-end are restated at year end rates. In case of items which are covered by forward exchange contracts. The difference between the year-end rate and rate on the date of the contract is recognized as exchange difference and realized gain or loss due to fluctuation is recognized as Forward Gain and Loss.

K Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events, and it is probable that there will be an outflow of resources. Liabilities which are of contingent nature are not provided but are disclosed at their estimated amount in the notes forming part of the accounts. Contingent assets are neither recognized nor disclosed in the financial statements.

L Investments

The Company is not having any investments but as a matter of accounting policy we follow below mentioned accounting policy:

Investments are classified into current and long-term investments. Investments that are readily realizable and intended to be held for not more than a year from the date on which such investments are made are classified as current investments. All other investments are classified as long-term investments.

Current investments are carried at lower of cost and fair value (net asset value in case of units of mutual fund) determined on an individual investment (category wise) basis. Long term investments are carried at cost. However, provision for diminution in value of long term investments is made to recognize a decline, other than temporary, on an individual investment basis.

Long term investments which are expected to be realized within twelve months from the balance sheet date are presented under 'current investments' as 'current portion of long term investments' in accordance with the current / non-current classification of investments as per Schedule III of the Companies Act,



The cost of investments comprises purchase price and directly attributable acquisition charges such as brokerage, fees and duties. If an investment is acquired in exchange, or part exchange, for another asset, the acquisition cost of the investment is determined by reference to the fair value of the asset given up or fair value of the investment acquired whichever is more clearly evident.

Investment transactions are accounted for on a trade date basis. In determining the holding cost of investments and the gain or loss on sale of investments, the 'weighted average cost' method is followed.

M Event occurring after the Balance Sheet Date

No significant events which could affect the financial position as on 31st March 2024, to a material extent have been reported by the management, after the Balance Sheet date till the signing the report.

N Prior period Items

Prior period expenses/income is accounted for under respective heads. Material items, if any, are disclosed separately by way of note.

O Financial derivatives and Hedging Transaction

The Company is not having any Financial derivatives and Hedging Transaction but as a matter of accounting policy we follow below mentioned accounting policy:

In respect of derivative contracts, premium paid and gains/losses on settlement are recognized in the Profit and Loss account except in case where they relate to the acquisition or construction of fixed assets, in which case, they are adjusted to the carrying cost of such assets.

P Earnings Per Share

The earning considered in ascertaining the Company's Earnings per Share (EPS) comprises the net profit after tax. The number of shares used in computing Basic and diluted EPS is weighted average number of shares outstanding during the year as per the guidelines of AS-20 and calculation of EPS is shown in notes to account.

Q Segment reporting

Accounting standards interpretation (ASI) 20 dated 14-02-2004, issued by the accounting standard board of ICAI, on AS-17, Segment reporting clarifies that in case by applying the definition of "Business Segment and Geographical Segment" given in AS-17, it is concluded that there is neither more than one Business Segment nor more than one Geographical segment, Segment information as per AS-17 is not required to be disclosed.

R Lease

Lease arrangements where risks and rewards incidental to ownership of an asset substantially vest with the lessor are classified as operating lease.

Rental expenses/license fees income received on assets obtained/given under operating lease arrangements are recognized on a straight-line basis as an expense in the statement of profit and loss over the lease term of the respective lease arrangement.

S Borrowing costs

Borrowing costs that are directly attributable to the acquisition, construction or development of a qualifying asset are capitalized as part of the cost of the respective asset till such time the asset is ready for its intended use. A qualifying asset is an asset which necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are expensed in the year in which they occur. Borrowing costs consist of interest, exchange difference arising from foreign currency borrowings to the extent they are treated as an adjustment to the borrowing cost and other costs that an entity incurs in connection with the borrowing of funds.



BRAINIAC HEALTHCARE PRIVATE LIMITED
(CIN: U85300GJ2021PTC124795)
Notes forming part of the Financial Statements

1 Share Capital

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Authorised Share Capital		
Equity Shares, of Rs. 10 each, 10000 (Previous Year -10000) Equity Shares	100.00	100.00
Issued, Subscribed and Fully Paid up Share Capital		
Equity Shares, of Rs. 10 each, 10000 (Previous Year -10000) Equity Shares paid up	100.00	100.00
Total	100.00	100.00

(i) Reconciliation of number of shares

Particulars	31 March 2024		31 March 2023	
	No. of shares	(Rs in '000)	No. of shares	(Rs in '000)
Opening Balance	10,000	100.00	10,000	100.00
Issued during the year	-	-	-	-
Deletion	-	-	-	-
Closing balance	10,000	100.00	10,000	100.00

(ii) Rights, preferences and restrictions attached to shares

The company has only one class of equity shares having par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share. The dividend, if any, proposed by the Board of Directors will be subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive assets of the company remaining after settlement of all liabilities.

(iii) Shares held by Holding company, its Subsidiaries and Associates

Particulars	31 March 2024		31 March 2023	
	No of Shares	(Rs in '000)	No of Shares	(Rs in '000)
NIL				

(iv) Details of Shares held by shareholders holding more than 5% of the aggregate shares in the company


Equity Shares	31 March 2024		31 March 2023	
	Name of Shareholder	No. of shares	In %	No. of shares
Krunal Prajapati	8,300	83.00%	8,300	83.00%
Rajesh Prajapati	1,000	10.00%	1,000	10.00%

(v) Shares held by Promoters at the end of the year 31 March 2024

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Krunal Prajapati	Equity	8,300	83.00%	
Rajesh Prajapati	Equity	1,000	10.00%	

Shares held by Promoters at the end of the year 31 March 2023

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Krunal Prajapati	Equity	8,300	83.00%	-5.00%
Rajesh Prajapati	Equity	1,000	10.00%	



(vi) Equity shares movement during 5 years preceding 31 March 2024

Particulars	Year 1	Year 2	Year 3	Year 4	Year 5
Number Of Equity Shares Bought Back	-	-	-	-	-
Number Of Preference Shares Redeemed	-	-	-	-	-
Number of Equity Share Issue as Bonus Share	-	-	-	-	-
Number of Preference Share Issue as Bonus Share	-	-	-	-	-
Number of Equity Shares Allotted For Contracts Without Payment Received In Cash	-	-	-	-	-
Number of Preference Shares Allotted For Contracts Without Payment Received In Cash	-	-	-	-	-

2 Reserves and Surplus

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Statement of Profit and loss		
Balance at the beginning of the year	(187.22)	(264.02)
Add: Profit/(loss) during the year	51.82	76.81
Balance at the end of the year	(135.40)	(187.22)
Total	(135.40)	(187.22)

3 Short term borrowings

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Unsecured Loans and advances from related parties	572.46	559.56
Total	572.46	559.56

4 Other current liabilities

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Expense Payables	493.82	303.45
Statutory dues Payable	0.73	5.80
Total	494.55	309.25



BRAINIAC HEALTHCARE PRIVATE LIMITED

(CIN: U85300GJ2021PTC124795)

Notes forming part of the Financial Statements

5 Property, Plant and Equipment

+UN#1q#*333,

Name of Assets	Gross Block		Depreciation and Amortization			Net Block			
	As on 01-Apr-23	Addition	Deduction	As on 31-Mar-24	As on 01-Apr-23	for the year	Deduction	As on 31-Mar-24	As on 31-Mar-23
(i) Property, Plant and Equipment									
COMPUTER	77.89	58.08		135.97	11.15	24.97		99.85	66.74
OFFICE EQUIPMENT	89.32	14.72		104.04	9.94	18.29		75.80	79.37
Total	167.20	72.81	-	240.01	21.09	43.26	-	175.65	146.11
Previous Year		167.20		167.20		21.09		146.11	
(ii) Intangible Assets									
Software	312.55	114.50		427.05	47.78	70.67		308.60	264.77
Total	312.55	114.50	-	427.05	47.78	70.67	-	308.60	264.77
Previous Year	144.50	168.05		312.55	3.04	44.74		264.77	141.46



BRAINIAC HEALTHCARE PRIVATE LIMITED

(CIN: U85300GJ2021PTC124795)

Notes forming part of the Financial Statements

6 Cash and cash equivalents

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Cash on hand	101.22	50.39
Balances with banks in current accounts	124.91	115.66
Total	226.13	166.05

7 Short term loans and advances

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Advances to suppliers	23.25	23.25
Balances with Government Authorities -GST Receivable	294.48	176.16
Total	317.73	199.41

8 Other current assets

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Incorporation expense	3.50	5.25
Total	3.50	5.25

9 Other Income

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Others -Subsidy income	1,370.12	929.52
Total	1,370.12	929.52

10 Purchases of stock in trade

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Purchases of goods	162.40	-
Total	162.40	-

11 Employee benefit expenses

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Salaries and wages	350.00	118.00
Total	350.00	118.00

12 Depreciation and amortization expenses

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Depriciation	113.93	65.83
Total	113.93	65.83



13 Other expenses

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Auditors' Remuneration	10.00	10.00
Power and fuel	20.79	1.64
Professional fees	48.00	120.76
Rent	173.29	120.00
Travelling Expenses	19.49	63.83
Miscellaneous expenses	136.94	45.81
Custom Duty	38.93	-
Forex Gain/Loss	7.70	2.41
Office Expense	9.83	13.48
Research & Development Exp	225.79	288.16
Website Expenses	1.21	6.70
Total	691.97	672.79

14 Tax Expenses

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Deferred Tax	-	(3.91)
Total	-	(3.91)

Significant components of Deferred Tax charged during the year

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Difference between book depreciation and tax depreciation	-	(3.91)
Total	-	(3.91)



BRAINIAC HEALTHCARE PRIVATE LIMITED
(CIN: U85300GJ2021PTC124795)
Notes forming part of the Financial Statements

15 Earning per share

Particulars	31 March 2024	31 March 2023
Profit attributable to equity shareholders (Rs in '000)	51.82	76.81
Weighted average number of Equity Shares	10,000	10,000
Earnings per share basic (Rs)	5.18	7.68
Earnings per share diluted (Rs)	5.18	7.68
Face value per equity share (Rs)	10	10

The earning considered in ascertaining the company's EPS comprises the profit available for shareholders i.e. profit after tax and statutory/regulatory appropriations. The number of shares used in computing Basic EPS is the weighted average number of shares outstanding during the year as per the guidelines of AS-20.

16 Auditors' Remuneration

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Payments to auditor as		
- Auditor	10.00	10.00
Total	10.00	10.00

17 Contingent Liabilities and Commitments

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Claims against the Company not acknowledged as debt		
- Income tax demands		
- Indirect tax demands		
Total	-	-

There are no capital commitments, other commitments and contingent liabilities as on 31st March 2024.

18 Expenditure made in Foreign Currencies

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Import of goods	352.25	41.89
Total	352.25	41.89

19 Related Party Disclosure

(i) List of Related Parties

Relationship

Krunal Prajapati	Director
Rajesh Prajapati	Director

(ii) Related Party Transactions

(Rs in '000)

Particulars	Relationship	31 March 2024	31 March 2023
Reimbursement of expenses to			
- Krunal Prajapati	Director	68.00	22.97
- Rajesh Prajapati	Director	120.00	120.00
Loans Received			
- Krunal Prajapati	Director	-	269.13
- Rajesh Prajapati	Director	12.90	-
Loan Repaid			
- Krunal Prajapati	Director	-	0.45



(iii) Related Party Balances

(Rs in '000)

Particulars	Relationship	31 March 2024	31 March 2023
Reimbursement of expenses			
- Krunal Prajapati	Director	96.26	62.97
- Rajesh Prajapati	Director	-	120.00
Loans Payable			
- Krunal Prajapati	Director	569.46	556.56
- Rajesh Prajapati	Director	3.00	3.00

Related party relationship is as identified by the Company and relied upon by the Auditors. Transactions are disclosed from / upto the date the relationship came into existence.

20 Managerial Remuneration

(Rs in '000)

Particulars	31 March 2024	31 March 2023
Directors Remuneration	300.00	90.00
Total	300.00	90.00

21 Ratio Analysis


Particulars	Numerator/Denominator	31 March 2024	31 March 2023	Change in %
(a) Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	0.51	0.43	20.23%
(b) Return on Equity Ratio	$\frac{\text{Profit after Tax}}{\text{Average Shareholder's Equity}}$	-84.52%	-61.14%	38.24%
(c) Return on Capital employed	$\frac{\text{Earning before interest and taxes}}{\text{Capital Employed}}$	-146.38%	-83.58%	75.13%
(c) Return on investment	$\frac{\text{Return on Investment}}{\text{Total Investment}}$	0.00%	0.00%	

Reasons for Variances

1. Return on equity ratio: Due to decrease in profit for the current year
2. Return on capital employed: Due to decrease in capital employed for the current year

22 Other Statutory Disclosures as per the Companies Act, 2013

Additional information as required by Para 5 of General Instructions for preparation of Statement of Profit and Loss (other than already disclosed) is either Nil or Not Applicable or complied with.



During the year, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company. Further, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Previous year's figures have been re-grouped / re-classified where necessary to conform to the current year's classification.

As per our report of even date
For PRADIP B. GANDHI & CO. LLP
Chartered Accountants
Firm's Registration No. 118674W/W101002


CA Amit Lakhtariya

Designated Partner
Membership No. 117820

UDIN: 24117820BKAUUR4927
Place: Ahmedabad
Date: 16 September 2024



For and on behalf of the Board of
BRAINIAC HEALTHCARE PRIVATE LIMITED

K. R. Prajapati

21/09/2024
20/09/2024
30/09/2024

KRUNAL PRAJAPATI	RAJESHBHAI PRAJAPATI
Director	Director
09274943	09274944

Place: Ahmedabad
Date: 16 September 2024

BRAINIAC HEALTHCARE PRIVATE LIMITED

Date: 16/09/2024

Dear Member,

You are cordially invited to attend the 03rd Annual General Meeting of the members of BRAINIAC HEALTHCARE PRIVATE LIMITED ('The Company') to be held on Wednesday, 25th September, 2024 At 2:30 P.M. at the registered office of the company at B-24, Vrundavan Park, Nr. Janta Nagar, Odhav, Ahmedabad, Gujarat, India-382415.

The notice of the meeting, containing the business to be transacted, is enclosed herewith.

Very Truly Yours,

K. R. Prajapati

KRUNAL PRAJAPATI
(Director)
DIN NO: - 09274943

Enclosure:

1. Notice to 03rd Annual General Meeting (AGM)

BRAINIAC HEALTHCARE PRIVATE LIMITED

SHORTER NOTICE

Shorter Notice is hereby given that the 03rd ANNUAL GENERAL MEETING of the members of **Brainiac Healthcare Private Limited** will be held on Wednesday, 25th September, 2024 at 2:30 P.M. at the registered office of the company at B-24, Vrundavan Park, Nr. Janta Nagar, Odhav, Ahmedabad, Gujarat, India-382415.

ORDINARY BUSINESS:

1. Adoption of financial statements:

To receive, consider and adopt the financial statement of the Company for the year ended March 31, 2024, including the audited balance sheet as at March 31, 2024, and the statement of profit and loss for the year ended on that date and the report of the board of director (the board) and Auditor thereon.

2. Ratification of auditors:

To ratify appoint of Pradip B Gandhi & Co. (FRN: 118674W), Chartered Accountants as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting and to authorise the Board of Directors to fix his remuneration for the financial year 2024-25.

Notes:

1. A member entitled to attend and vote at the annual general meeting (the "Meeting") is entitled to appoint a proxy to attend and vote on a poll instead of himself and the proxy need not be a member of the Company. The instrument appointing the proxy should, however, be deposited at the registered office of the Company not less than forty-eight hours before the commencement of the Meeting.
2. The Meeting shall be deemed to be held at the registered office of the company at B-24, Vrundavan Park, Nr. Janta Nagar, Odhav, Ahmedabad, Gujarat, India-382415.
3. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Companies Act, 2013, relevant documents referred to in the notice, and the statements will be available for inspection by the members at the registered office of the company on all working days, during business hours up to and on the date of AGM.
4. Corporate members intending to authorize their representatives to attend the Meeting are requested to send a scanned certified copy of the board resolution (pdf/jpeg format) authorizing their representative to attend and vote on their behalf at the Meeting. The said Resolution/Authorization shall be sent to the company by email through their registered email address to krunalprajapati778@gmail.com or in hard copy at the registered office of the Company before the scheduled time of commencement of the meeting.
5. Members attending the AGM through VC/ OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.
6. Members in case of any queries may send an email to krunalprajapati778@gmail.com Further, in case of voting is conducted by way of poll, Members shall be requested to send their vote on this Email ID.

REG. OFFICE: B-24, VRUNDAVAN PARK NR. JANTA NAGAR, ODHAV AHMEDABAD 382415
CIN: U85300GJ2021PTC124795, M. No:- 8141671751
Mail: krunalprajapati778@gmail.com

BRAINIAC HEALTHCARE PRIVATE LIMITED

7. Route map attached for the address of AGM held.



By Order of the Board of Directors
For Brainiac Healthcare Private Limited

K. R. Prajapati

Krunal Prajapati
Director
DIN- 09274943

Place: Ahmedabad
Date: 16/09/2024

BRAINIAC HEALTHCARE PRIVATE LIMITED

6. The State of the Company Affairs

The Company is a private Company domiciled in India and incorporated under the provisions of the Companies Act 2013. The Company is recognized as startup by the Department for Promotion of Industry and Internal Trade. The Startup is working in 'Healthcare & Lifesciences' Industry and 'Medical Devices Biomedical'.

7. Material changes and commitments

There are no material changes and commitments which have occurred between the end of the financial year to which the financial statements relate and the date of this Report that impact on financial position of the Company.

8. Reasons for Revision of Financial Statement or Report

There is no revision of financial statement and report of the Company.

9. Dividend

No Dividend was declared for the current financial year.

10. Reserves

The Company has not transferred any profit to reserves as at the end of financial year under review.

11. Directors & Key Managerial Personnel

No Directors were appointed or has resigned from the company during the year under review.

12. Independent Director

The provisions of Section 149 of Companies Act, 2013 read with Rule 4 of Companies (Appointment and Qualification of Directors) Rules, 2014 for appointment of Independent Directors do not apply to the Company.

13. Details of Adequacy of Internal Financial Controls

The Company is well equipped with adequate internal financial controls. The Company has a continuous monitoring mechanism which enables the organisation to maintain with the same standard of the control systems and helps them in managing any default on timely basis because of strong reporting mechanisms followed by the Company.

14. Formal Evaluation by Board of Its own Performance

Being a private limited company, the Statement in respect of formal evaluation by the Board of its own performance and that of its committees and individual directors are not applicable to the Company.

REG. OFFICE: B-24, VRUNDAVAN PARK NR. JANTA NAGAR, ODHAV AHMEDABAD 382415

CIN: U85300GJ2021PTC124795, M. No:- 8141671751

Mail: krunalprajapati778@gmail.com

BRAINIAC HEALTHCARE PRIVATE LIMITED

15. Issue of Equity Shares with Differential Voting Rights / Sweat Equity Shares / Employee Stock Option Scheme

During the year under review, the Company has not issued any equity shares with differential voting rights or sweat equity shares or employee stock option scheme.

16. Disclosure of Composition of Audit Committee and Providing Vigil Mechanism

As the Company is neither listed Company nor falling under criteria laid down under rule 7 of Companies (Meetings of Board and its Powers) Rules, 2014, hence the vigil mechanism is not applicable to the Company during the financial year under review.

17. Corporate Social Responsibility (CSR)

The Company is not covered under class of Companies as specified under Section 135 of the Companies Act, 2013, hence, reporting requirement pertaining to CSR Committee and CSR is not applicable to our Company during the year under review under section Sec 134(3)(o) read with Rule 9 of Companies (Accounts) Rules, 2014 and Section 135 of the Companies Act, 2013.

18. Analysis of Remuneration

The Company is not listed on any recognized stock exchange; hence disclosure regarding the ratio of the remuneration of each Director to the median employee's remuneration and other details are not applicable to the Company.

19. Policy on Director's Appointment & Remuneration

Requirement of Nomination and Remuneration Committee is not applicable to the Company; however, the Company's remuneration policy is directed towards rewarding performance based on review of achievements periodically. The remuneration policy is in consonance with the existing industry practice.

20. Risk Management Policy

As per the applicable requirements of the Companies Act, 2013 a risk management policy/plan of the Company is to ensure sustainable business growth with stability and to promote a pro-active approach in reporting, evaluating and resolving risks associated with the business. In order to achieve the key objective, the policy establishes a structured and disciplined approach to Risk Management, in order to guide decisions on risk related issues.

21. Particulars of Employees

The disclosures pertaining to remuneration and other details of Directors and employees as required under Section 197(12) of the Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 have not been provided as there are no such employees to whom this rule is applicable.

22. Deposits

During the year under report, your Company has not accepted any deposits pursuant to Section 73 of the Companies Act, 2013. Hence, disclosures as required pursuant to Rule 8(5)(v) of Companies (Accounts) Rules, 2014 are not applicable for the financial year under review.

BRAINIAC HEALTHCARE PRIVATE LIMITED

23. Number of meetings of the board

The board met many times during the financial year. The intervening gap between any two meetings was within the period prescribed in the section 173 The Companies Act, 2013.

The details of meetings held during the year is as per Annexure - 2

24. Information pursuant to Sec. 134 of the Companies Act, 2013

Details pursuant to the provisions of Sec. 134 of the Companies Act, 2013:

A) Details regarding Foreign exchange earnings and expenditures.

Earning in foreign exchange: -

Particulars	Accrued	Actual Inflow during the year	Amount in c
Export of Goods (Net off return)	-	-	

Expenses incurred in Foreign Currency: -

Particulars	Accrued	Actual Outflow during the year
Import of Goods	3,44,156	3,52,246

- B) Details regarding Technology Absorption is Nil
C) Details regarding Conservation of Energy is Nil

25. Cost Records

Maintenance of cost records as specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013, is not applicable to the Company.

26. Corporate Governance

Our Company is an unlisted entity; hence the requirement of Corporate Governance is not applicable to our Company during the financial year under review.

27. Extract of Annual Return

Pursuant to substitution made in Section 92(3) of the Companies Act, 2013 vide the Companies (Amendment) Act, 2017; the requirement of including an extract of the annual return in the Board's report has been omitted.

28. Particulars of Loans, Investments or Guarantees under Section 186 of The Companies Act, 2013

There are no loans, guarantees and investments covered under section 186 of the Companies Act, 2013.

REG. OFFICE: B-24, VRUNDAVAN PARK NR. JANTA NAGAR, ODHAV AHMEDABAD 382415

CIN: U85300GJ2021PTC124795, M. No:- 8141671751

Mail: krupalprajapati778@gmail.com

BRAINIAK HEALTHCARE PRIVATE LIMITED

29. Related Party Transaction

All the contract or arrangements or transactions entered by company with related parties are conducted in the transparent manner with the interest of the company in stake holders as utmost priority. Since all related party transactions entered in to by the company were in the ordinary course of business and were on arm's length basis Form AOC-2 is not applicable and is as per Annexure-1.

30. Material Orders Passed by the Regulator/Court

During the year under review, there is no significant and material order passed by the regulators or courts or tribunals impacting the going concern status and Company's operations in future.

31. Disclosure under the Sexual Harassment of Women at Work Place (Prevention, Prohibition and Redressal) Act, 2013:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary) are covered under this policy. There was no case reported under the Act during the financial year under review.

32. Instances of Fraud, If any Reported by the Auditors

There have been no instances of fraud reported by the Auditors under Section 143(12) of the Companies Act, 2013.

33. Details of Insolvency and Bankruptcy Code, 2013

The Company has not made any application or nor any proceeding pending under the Insolvency and Bankruptcy code, 2016 (31 of 2016) during the year under review. There are NIL such cases as at the end of the financial year.

34. Environment and Safety

The Company is conscious of the importance of environmentally clean and safe operations. The Company's policy requires conduct of operations in such a manner, so as to ensure safety of all concerned, compliances of environmental regulations and preservation of natural resources.

35. Disclosure of Accounting Treatment

In the preparation of the financial statements, the Company has followed the Accounting Standards referred to in Section 133 of the Companies Act, 2013. The significant accounting policies which are consistently applied are set out in the Notes to the Financial Statements.

36. Secretarial Standards

The Company complies with the Secretarial Standards issued by the Institute of Company Secretaries of India which are mandatorily applicable to the Company.

BRAINIAC HEALTHCARE PRIVATE LIMITED

37. Disclosures

The Company has not entered into any transaction of material nature with the Promoters, the Directors or the Management that may have any potential conflict with the interest of the Company.

38. Auditors

At the 1st AGM which was held on 09th August 2022, the Members have approved appointment of M/s Pradip B. Gandhi Co., Chartered Accountant (FRN: 011864W) as Statutory Auditors of the company to hold the office for a period of five years from conclusion of that AGM till the conclusion of 06th AGM, subject to ratification of their appointment by Members at every AGM, if so required under the act.

39. Web Link of Annual Return

This clause is not applicable during the financial year 2023-24 as the company does not maintain any website for placing of Annual Return.

40. Directors Responsibility Statement

As required under Section 134(5) of the Companies Act, 2013, the Directors hereby confirm that:

- i. In the preparation of the annual accounts, the applicable accounting standards has been followed along with proper explanation relating to material departures, if any.
- ii. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profits of the Company for that period.
- iii. The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- iv. The Directors had prepared the annual accounts on a 'Going Concern' basis.
- v. The Directors had devised proper system to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

REG. OFFICE: B-24, VRUNDAVAN PARK NR. JANTA NAGAR, ODHAV AHMEDABAD 382415

CIN: U85300GJ2021PTC124795, M. No:- 8141671751

Mail: krunalprajapati778@gmail.com

BRAINIAC HEALTHCARE PRIVATE LIMITED

41. Acknowledgement

Your directors wish to place on records their sincere thanks for the valuable assistance and co-operations received from the Banks, Customers, Suppliers & various Government Authorities. Your directors also take on record the appreciation for the contribution and hard work of employees across all levels, without their commitment, inspiration and hard work, your Company consistent growth would not have been possible.

For and on behalf of the order of the Board
Brainiac Healthcare Private Limited

K. R. Prajapati

*૨૧૨૨૧૬૨૧૨ ૨૦૧૬૦૩૦૧૬
૩૦૧૫૪*

KRUNAL PRAJAPATI
DIN: 09274943
DIRECTOR

RAJESHBHAI PRAJAPATI
DIN: 09274944
DIRECTOR

Date: 16/09/2024
Place: Ahmedabad

BRAINIAC HEALTHCARE PRIVATE LIMITED

Annexure - 1

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
	Name (s) of the related party & nature of relationship	
	Nature of contracts/arrangements/transaction	
	Duration of the contracts/arrangements/transaction	
	Salient terms of the contracts or arrangements or transaction including the value, if any	N.A.
	Justification for entering into such contracts or arrangements or transactions'	
	Date of approval by the Board	
	Amount paid as advances, if any	
	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	

2. Details of contracts or arrangements or transactions at Arm's length basis.

SL. No.	Particulars	Details
	Name (s) of the related party & nature of relationship	
	Nature of contracts/arrangements/transaction	
	Duration of the contracts/arrangements/transaction	
	Salient terms of the contracts or arrangements or transaction including the value, if any	N.A.
	Date of approval by the Board	
	Amount paid as advances, if any	

REG. OFFICE: B-24, VRUNDAVAN PARK NR. JANTA NAGAR, ODHAV AHMEDABAD 382415

CIN: U85300GJ2021PTC124795, M. No:- 8141671751

Mail: krunalprajapati778@gmail.com

BRAINIAC HEALTHCARE PRIVATE LIMITED

Annexure – 2

The details of meetings held for the financial year ending as on 31st March, 2024

Type	Date	KRUNAL PRAJAPATI	RAJESHBHAI PRAJAPATI
AGM	14/09/2023	Present	Present
BM	03/04/2023	Present	Present
BM	29/06/2023	Present	Present
BM	19/08/2023	Present	Present
BM	16/11/2023	Present	Present
BM	12/02/2024	Present	Present

BRAINIAC HEALTHCARE PRIVATE LIMITED

LIST OF SHAREHOLDERS AS ON 31ST MARCH, 2024

S.NO.	NAME	NO. OF SHARES	% OF HOLDING
1	KRUNAL PRAJAPATI	8300	83%
2	RAJESH PRAJAPATI	1000	10%
3	CIIE INITIATIVE	200	2%
4	CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS	500	5%
	TOTAL	10000	100%

For and on behalf of the order of the Board
Brainiac Healthcare Private Limited

K.R. Prajapati

કરુણા પ્રજાપતી

KRUNAL PRAJAPATI
DIN: 09274943
DIRECTOR

RAJESHBHAI PRAJAPATI
DIN: 09274944
DIRECTOR

BRAINIAC HEALTHCARE PRIVATE LIMITED

LIST OF DIRECTORS AS ON 31ST MARCH, 2024

S.NO.	NAME	DIN	DESIGNATION	DATE OF APPOINTMENT
1	KRUNAL PRAJAPATI	09274943	DIRECTOR	09/08/2021
2	RAJESHBHAI PRAJAPATI	09274944	DIRECTOR	09/08/2021

For and on behalf of the order of the Board
Brainiac Healthcare Private Limited

K.R. Prajapati

ક્રુણલ પ્રજાપતી

KRUNAL PRAJAPATI
DIN: 09274943
DIRECTOR

RAJESHBHAI PRAJAPATI
DIN: 09274944
DIRECTOR